Remedium Capital Partners, LLC

Est. AUM

$319.8M

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	Spyre Therapeutics Inc	COM	$96.2M	1907327	30.09%	SOLE
2	Oruka Therapeutics Inc	COM	$92.7M	1889115	28.98%	SOLE
3	Damora Therapeutics Inc	COM	$53.0M	2045473	16.57%	SOLE
4	Apogee Therapeutics Inc	COM	$49.1M	583591	15.36%	SOLE
5	Jade Biosciences Inc	COM	$22.2M	1577750	6.93%	SOLE
6	Crescent Biopharma Inc	COM	$6.6M	361250	2.08%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.